close
References
  1. Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020:26(suppl 6):1-158.
  2. Forsyth AL, Witkop M, Lambing A, et al. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Prefer Adherence. 2015;9:1549-1560.
  3. Kloosterman F, Zwagemaker AF, Abdi A, Gouw S, Castaman G, Fijnvandraat K. Hemophilia management: huge impact of a tiny difference. Res Pract Thromb Haemost. 2020;4(3):377-385.
  4. Boeriu E, Arghirescu TS, Serban M, et al. Challenges in the diagnosis and management of non-severe hemophilia. J Clin Med. 2022;11(12):3322.
  5. Hassan S, Monahan RC, Mauser-Bunschoten EP, et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018. J Thromb Haemost. 2021;19(3):645-653.
  6. Krumb E, Hermans C. Living with a "hemophilia-free mind" - the new ambition of hemophilia care? Res Pract Thromb Haemost. 2021;5(5):e12567.
  7. Cassis FR, Querol F, Forsyth A, Iorio A; HERO International Advisory Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia. 2012;18(3s.1):e101-114.
  8. Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Adv. 2020;4(11):2451-2459.
  9. von Mackensen S, Kalnins W, Krucker J, et al. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia. 2017;23(4):566-574.
  10. Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10(6):689-697.
  11. Swan D, Mahlangu J, Thachil J. Non-factor therapies for bleeding disorders: a primer for the general haematologist. E J Haem. 2022;3(3):584-595.
  12. Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL. Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study. Blood Coagul Fibrinolysis. 2016;27(7):753-760.
  13. Young G. Nonfactor therapies for hemophilia. Hemasphere. 2023;7(6):e911.
  14. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818.
  15. Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: the story so far. J Thromb Haemost. 2019;17(8):1269-1272.
  16. Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137(16):2231-2242.
  17. Food and Drug Administration. Emicizumab-kxwh. Prescribing information. Updated March 2023. Accessed November 21, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761083s011lbl.pdf
  18. Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127-2138.
  19. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
  20. Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295-e305.
  21. Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies. Blood. 2018;132(suppl 1):633.
  22. Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost. 2019;119(9):1384-1393.
  23. Parisi K, Kumar A. Emicizumab. Updated July 4, 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Accessed October 15, 2023. https://www.ncbi.nlm.nih.gov/books/NBK559180
  24. Young G, Lenting PJ, Croteau SE, Nolan B, Srivastava A. Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost. 2023;7(4):100179.
  25. Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023;401(10386):1427-1437.
  26. Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023;10(5):e322-e332.
  27. Alnylam. Alnylam provides pipeline update on fitusiran and givosiran investigational RNAi therapeutic programs. September 7, 2017.
  28. Peyvandi F, Garagiola I, Abbattista M. Fitusiran in haemophilia: a breakthrough drug with many unknowns. Lancet. 2023;401(10386):1400-1401.
  29. Gualtierotti R, Pasca S, Ciavarella A, et al. Updates on novel non-replacement drugs for hemophilia. Pharmaceuticals (Basel). 2022;15(10):1183.
  30. National Hemophilia Foundation. Sanofi revises fitusiran dosing regimen to mitigate risk of vascular thrombosis. February 22, 2021. Accessed October 13, 2023. https://www.hemophilia.org/news/sanofi-revises-fitusiran-dosing-regimen-to-mitigate-risk-of-vascular-thrombosis
  31. Wang S, Kattula S, Ismail A, Leksa N, vanDer Flier A, Salas J. Reducing antithrombin in plasma to levels observed in fitusiran-treated patients does not interfere with coagulation assays. Blood. 2020;136(suppl 1):10.
  32. Matsushita T, Shapiro A, Abraham A, et al; explorer7 Investigators. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389(9):783-794.
  33. Chowdary P, Angchaisuksiri P, Apte S, et al. Concizumab prophylaxis in patients with haemophilia A or B without inhibitors: Efficacy and safety results from the primary analysis of the phase 3 explorer8 study (Abstract OC 59.1). Presented at International Society on Thrombosis and Haemostasis Congress; June 24-28, 2023; Montreal, Canada.
  34. Seremetis SV, Cepo K, Skovgaard Rasmussen J, et al. Risk mitigation strategy for concizumab clinical trials after pause due to non-fatal thrombotic events. Blood. 2020;136(suppl 1):40.
  35. Seremetis S, Cepo K, Rasmussen J, et al. Risk mitigation strategy for concizumab clinical trials re-initiation after pause due to non-fatal thrombotic events. Haemophilia. 2021;27(suppl 2):124.
  36. National Hemophilia Foundation. FDA requests additional information on concizumab from Novo Nordisk. May 5, 2023. Accessed October 15, 2023. https://www.hemophilia.org/news/fda-requests-additional-information-on-concizumab-from-novo-nordisk
  37. Keam SJ. Concizumab: first approval. Drugs. 2023;83(11):1053-1059.
  38. Pfizer. Pfizer announces positive marstacimab results from pivotal phase 3 hemophilia A and B trial. May 30, 2023.